We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp (Non Applicable)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04960891
Expanded Access Status : Available
First Posted : July 14, 2021
Last Update Posted : January 21, 2022
Sponsor:
Collaborator:
Clinigen, Inc.
Information provided by (Responsible Party):
Immunocore Ltd

Brief Summary:

This Expanded Access Program aims to:

  1. Provide access to tebentafusp for mUM patients.
  2. Provide access to tebentafusp for patients, who were on the control arm of the randomized controlled Phase II trial (IMCgp100-202) and were unable to crossover during the specified window.
  3. Ensure that patients, who are benefiting from tebentafusp treatment while participating in an ongoing Immunocore sponsored clinical study (e.g., IMCgp100-102 or IMCgp100-201), may continue tebentafusp treatment on this Programme once the ongoing trial has met all of its key primary and secondary objectives.

Condition or disease Intervention/treatment
Uveal Melanoma Drug: Tebentafusp

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: A Cohort IND Expanded Access Program (EAP) for Tebentafusp for Treatment of HLA-A*02:01 Positive Patients With Metastatic Uveal Melanoma



Intervention Details:
  • Drug: Tebentafusp
    Concentrate solution for intravenous infusion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

Age

  1. Male or female patients age ≥ 18 years of age at the time of first dose

    Type of Participant and Disease Characteristics

  2. Histologically or cytologically confirmed metastatic UM or unresectable UM patients
  3. HLA-A*02:01 positive
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

    Informed Consent

  5. Ability to provide and understand informed consent prior to procedures [if required]

    Contraception

  6. Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 1 week after the final dose of the program intervention; cessation of birth control after this point shall be discussed with a responsible physician.

    1. Pregnant or lactating women are prohibited from enrolling on this program.
    2. Male participants are not allowed to donate sperm from the time of enrolment until 3 months post- administration of program interventions.

Exclusion Criteria:

Disease Under Study and Prior Anticancer Therapy

  1. Presence of untreated or symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or cord compression. NOTE: Participants with treated CNS lesions may enroll provided all of the following apply:

    1. Treated CNS lesions must be radiographically stable for ≥ 2 weeks after intervention (surgery and/or radiation).
    2. Participants must be neurologically stable off systemic corticosteroids for at least 2 weeks prior to first planned administration of tebentafusp.
  2. Receipt of anticancer therapy for the disease under study within the following times prior to the first planned dose of program intervention:

    1. Cellular therapies (e.g., T-cell therapies): 90 days.
    2. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)- targeted immunotherapies (e.g., ipilimumab): 28 days
    3. All other immunotherapies, including PD-(L)1-targeted immunotherapies (e.g., atezolizumab, pembrolizumab): 21 days
    4. All other systemic therapies: 14 days
    5. Radiotherapy: 14 days (excepting palliative radiotherapy to a limited field [e.g., for a focally painful tumor mass], which may be administered within 14 days provided there are no ongoing related Grade 2 or higher toxicities)

    Medical Conditions and Concomitant Medications

  3. Systemic treatment with steroids or any other immunosuppressive drug use within 2 weeks of the planned first dose of program intervention, with the following exceptions:

    1. Treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ≤ 12 mg daily or the equivalent.
    2. Local steroid therapies (e.g., optic, ophthalmic, intra- articular, or inhaled medications) are acceptable.
    3. Premedication for allergy to contrast reagent.
    4. Steroids for management of CNS metastases > 2 weeks prior to the planned first dose of program intervention.
  4. Any relevant medical condition, which in the opinion of the treating physician, would prevent the participant enrolling into the Program due to concerns related to safety, compliance with procedures, or interpretation of program results.
  5. Chronic viral infections as indicated below. NOTE: Testing for hepatitis C virus (HCV) status prior to enrollment is not necessary unless clinically indicated.

    1. Known history of human immunodeficiency virus (HIV) infection.
    2. Known HBV infection, unless on stable anti-viral therapy for > 4 weeks prior to the planned first dose of program intervention and viral load confirmed as undetectable during Screening.
    3. Known HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable during Screening.

    Diagnostic Assessments

  6. Participant with an out-of-range Screening laboratory values defined as shown below. NOTE: Hematology evaluations must be performed ≥ 7 days from any blood or blood product transfusion and ≥ 14 days from any dose of hematologic growth factor.

    1. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 30 mL/minute
    2. Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN
    3. Alanine aminotransferase > 5 × ULN
    4. Aspartate aminotransferase > 5 × ULN
    5. Platelet count < 50 × 109/L
    6. Hemoglobin < 8 g/dL
  7. Clinically significant cardiac disease or impaired cardiac function, including any of the following:

    1. Congestive heart failure (New York Heart Association Class ≥ 3)
    2. Uncontrolled hypertension defined as systolic blood pressure [BP] > 160 mmHg or diastolic BP > 110 mmHg with the following requirements:
    1. If initial measurement is elevated, additional assessments should be taken where each assessment is the mean value of 3 measurements taken at least 5 minutes apart.
    2. Eligibility is based on the average of at least 2 assessments taken at least 1 hour apart.
    3. Acute myocardial infarction or unstable angina pectoris < 6 months prior to the planned first dose of program intervention

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04960891


Contacts
Layout table for location contacts
Contact: Medical Information 1-844-IMMUNO-1 medical.information@immunocore.com

Sponsors and Collaborators
Immunocore Ltd
Clinigen, Inc.
Layout table for additonal information
Responsible Party: Immunocore Ltd
ClinicalTrials.gov Identifier: NCT04960891    
Other Study ID Numbers: IMCgp100-402 EA
First Posted: July 14, 2021    Key Record Dates
Last Update Posted: January 21, 2022
Last Verified: January 2022
Keywords provided by Immunocore Ltd:
Melanoma
Uveal Cancer
IMCgp100
Immunotherapy
Tebentafusp
Ocular Melanoma
Eye Melanoma
Uveal Melanoma
Gp100
TCR
Bispecific T cell receptor fusion protein
ImmTAC
Immune mobilizing monoclonal T cell receptor against cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Uveal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Uveal Diseases